David Andrews
Company: Imvax
Job title: Chief Medical Officer
Seminars:
Goldspire™: A Biologic-Device Combination Immunotherapy that Induces Preclinical Anti-Tumor Responses Against Multiple Solid Tumors Shows Clinical Activity in Glioblastoma 9:00 am
Utilizing a biodiffusion chamber releasing tumor antigens and an IGF1R antisense for effective treatment of glioblastoma Realizing the platform configuration to maximize immunogenic cell death Exploring long-term survival and immunity of glioblastoma patients receiving individualized immunotherapyRead more
day: Conference Day One